<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68880">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995240</url>
  </required_header>
  <id_info>
    <org_study_id>NL40501.018.12</org_study_id>
    <nct_id>NCT01995240</nct_id>
  </id_info>
  <brief_title>Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study</brief_title>
  <acronym>REMP</acronym>
  <official_title>Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at
      an early stage. Preferably, these markers could be determined non-invasively and provide
      insight into the biology of pancreatic cancer. Several MR techniques can serve for this
      purpose. However, optimalisation of these techniques is needed and their reproducibility
      should be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:

      Novel predictive markers are needed to determine treatment efficacy in pancreatic cancer at
      an early stage. Preferably, these markers could be determined non-invasively and provide
      insight into the biology of pancreatic cancer. Several MR techniques can serve for this
      purpose. However, optimalisation of these techniques is needed and their reproducibility
      should be assessed.

      Objective of the study:

      To optimize DCE-MRI, T2* MRI and DWI in pancreatic cancer at 3T and investigate its
      reproducibility.

      Study design:

      In the first part of the study, patients with pancreatic cancer will undergo an MR
      measurement protocol once at 3T, to optimize MR techniques (DCE-MRI, T2* MRI and DWI). In
      the second part of the study, to assess reproducibility patients will undergo the MR
      measurement protocol twice within one week before start of any treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.</measure>
    <time_frame>Within 1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess reproducibility, 15 patients will undergo the MR measurement protocol twice within one week before start of any treatment.
Reproducibility of; DWI: mean ADC of the whole tumor. DCE: mean Ktrans of the whole tumor. T2*: average value of the whole tumor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI with immunohistochemically determined markers of vascularity, hypoxia and stroma in pancreatic tumor tissue</measure>
    <time_frame>Within 1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>In those patients for whom tumor tissue is available which has not been treated with radiation or chemotherapy, DCE-MRI, T2* MRI and DWI will be compared with immunohistochemical markers of vascularity, hypoxia and stroma (e.g. CD-31, HIF1-alfa, CA9, GLUT1, PAI-1, VEGF, anti-SMA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Optimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reproducibility</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For determination of the reprodicibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol</intervention_name>
    <description>0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush</description>
    <arm_group_label>Optimization</arm_group_label>
    <arm_group_label>Reproducibility</arm_group_label>
    <other_name>Gadovist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pancreatic tumors, with histological or cytological proof of
             adenocarcinoma or a high suspicion on CT imaging.

          -  Any tumor with a size â‰¥ 1cm

          -  WHO-performance score 0-2

          -  Written informed consent

        Exclusion Criteria:

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering adequate informed consent or compliance with the study protocol.

          -  Contra-indications for MR scanning, including patients with a pacemaker, cochlear
             implant or neurostimulator; patients with non-MR compatible metallic implants in
             their eye, spine, thorax or abdomen; or an aneurysm clip in their brain; patients
             with severe claustrophobia.

          -  Renal failure (GFR &lt; 30 ml/min) hampering safe administration of Gadolinium
             containing MR contrast agent.

          -  For the reproducibility part of the protocol: surgery, radiation and/or chemotherapy
             foreseen within the timeframe needed for MRI scanning.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H WM van Laarhoven, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanneke WM van Laarhoven, M.D., Ph.D.</last_name>
      <phone>0031 20 5665955</phone>
      <email>h.vanlaarhoven@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>H WM van Laarhoven, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>R Klaassen, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>H.W.M. van Laarhoven</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>MRI</keyword>
  <keyword>reproducibility</keyword>
  <keyword>optimalization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
